Test Page
Braintumor Website

ARCHIVE pologies, but the page you requested could not be found. Perhaps searching will help.

NCT00045968 DCVax (Autologous dendritic cells pulsed with tumor lysate) Y States: AR CA CO DC FL IL IN KS MA MI MN MO NJ NY NC OH PA RI SC TN TX WA; London, UK; Dresden, Germany glioblastoma ages 18-70 newly diagnosed 3 yes No September 2015 June 2014 300
ClinicalTrials.gov data Name of therapy Location of trial Tumor type Adult or child Newly diagnosed or recurrent Phase Requires tumor sample? Estimated primary completion date Last verified Estimated enrollment (patients)
NCT00045968 DCVax (Autologous dendritic cells pulsed with tumor lysate) States: AR CA CO DC FL IL IN KS MA MI MN MO NJ NY NC OH PA RI SC TN TX WA. London, UK glioblastoma ages 18-70 newly diagnosed 3 yes September 2014 December 2013 300
NCT01480479 Rindopepimut (EGFRvIII vaccine) States: AL AZ AR CA CT DE FL GA HI IL IA KY LA MD MA MI MN MO NE NH NJ NY NC OH OR PA SC TN TX UT VT VA WA WI. Australia Austria Belgium Brazil Canada Colombia Czech R. France Germany Greece Hungary India Israel Italy Mexico Netherlands NewZealand Peru Spain Switzerland Taiwan Thailand UK glioblastoma adult newly diagnosed 3 surgical resection required November 2016 February 2014 700
NCT01635283 Autologous dendritic cells pulsed with tumor lysate Jonsson Comprehensive Cancer Center (Los Angeles) grade 2 glioma adult either 2 yes December 2016 August 2013 18
NCT01204684 Autologous dendritic cells pulsed with tumor lysate, +/- resiquimod or POLY ICLC Jonsson Comprehensive Cancer Center (Los Angeles) grade III-IV glioma adult either 2 yes September 2014 August 2013 60
NCT01498328 Rindopepimut (EGFRvIII vaccine) plus bevacizumab (trial name ReACT) States: AL AZ CA CO FL GA IL MD MA MI MN MO NV NJ NY NC OH OR PA RI TX UT WA glioblastoma (EGFRvIII positive) adult recurrent 2 no June 2015 February 2014 168
NCT02017717 Nivolumab or Nivolumab Combined With Ipilimumab (Yervoy) Versus Bevacizumab States: CA CT FL GA MD MA NY NC TN. 4 locations in Italy glioblastoma adult recurrent 2 no January 2018 March 2014 260
NCT01814813 Bevacizumab with or without Heat Shock Protein-Peptide Complex-96 (Prophage) States: CA FL IL IN MI MO MT NE NC OH OK SC VA resectable glioblastoma adult recurrent 2 yes April 2016 September 2013 222
NCT01454596 T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor NIH Clinical Center, Bethesda, MD glioblastoma, gliosarcome (EGRFvIII positive) 18-66 years recurrent or progressive 1/2 no September 2018 January 2014 160
NCT01920191 Intradermal IMA950 Peptide-based Vaccine plus Poly-ICLC University Hospital (Geneva, Switzerland) glioblastoma (HLA-A2 positive) adult newly diagnosed 1/2 no August 2014 August 2013 16
NCT01808820 Autologous tumor cells pulsed with tumor lysate University of Miami Sylvester Comprehensive Cancer Center grade III-IV glioma over age 13 recurrent 1 yes July 2018 February 2014 20
NCT01792505 Dendritic cells pulsed with tumor lysate, imiquimod cream Cedars-Sinai Medical Center (Los Angeles) malignant glioma adult 1 yes October 2014 February 2013 89
NCT01144247 Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 Jonsson Comprehensive Cancer Center (Los Angeles) malignant glioma or meningioma adult recurrent 1 no; surgery required July 2015 August 2013 15
NCT01250470 SVN53-67/M57-KLH Survivin peptide vaccine Roswell Park Cancer Institute (Buffalo, New York) malignant glioma (survivin-positive) adult recurrent or progressive 1 no September 2014 February 2014 9
NCT01967758 ADU-623 (EGFRvIII vaccine) Providence Cancer Center (Portland, Oregon) grade III astrocytoma, glioblastoma adult after standard of care 1 tissue required for testing October 2016 October 2013 38
NCT02010606 Autologous Dendritic Cells Pulsed With Lysate Derived From an Allogeneic Glioblastoma Stem-like Cell Line Cedars-Sinai Medical Center (Los Angeles) glioblastoma adult either 1 no; post-surgery minimal residual tumor required October 2018 December 2013 40
NCT02049489 Autologous CD-133 DC Vaccine (ICT-121) Cedars Sinai Medical Center, Los Angeles glioblastoma (HLA A2 positive) ages 18-80 recurrent 1 no; post-surgery minimal residual tumor required January 2015 January 2014 20
NCT00890032 Dendritic cells loaded with brain tumor stem cell mRNA Duke University Medical Center, Durham, North Carolina, USA glioblastoma adult recurrent 1 yes September 2015 January 2014 50


This page was created on 03/04/2014 and last updated on 11/26/2016



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites